Narrow search
Showing 1 - 8 of 8
Cover Image
HETEROGENEITY IN ACTION: THE ROLE OF PASSIVE PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH
Basu, Anirban; Jena, Anupam B.; Goldman, Dana P.; … - In: Health Economics 23 (2014) 3, pp. 359-373
ABSTRACT Despite the goal of comparative effectiveness research (CER) to inform patient‐centered care, most studies fail to account for the patient‐centeredness of care that already exist in practice, which we denote as passive personalization (PP). Because CER studies describe the average...
Persistent link: https://www.econbiz.de/10011005363
Cover Image
RESPONSE TO EPSTEIN'S COMMENT ON “HETEROGENEITY IN ACTION”
Basu, Anirban; Jena, Anupam B.; Goldman, Dana P.; … - In: Health Economics 23 (2014) 3, pp. 376-378
Persistent link: https://www.econbiz.de/10011005366
Cover Image
Erratum: Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA
Goldman, Dana; Lakdawalla, Darius; Philipson, Tomas J.; … - In: Health Economics 19 (2010) 12, pp. 1510-1510
Persistent link: https://www.econbiz.de/10008741247
Cover Image
Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA
Goldman, Dana; Lakdawalla, Darius; Philipson, Tomas J.; … - In: Health Economics 19 (2010) 10, pp. 1109-1116
Persistent link: https://www.econbiz.de/10008643999
Cover Image
The world-wide growth in obesity: an economic research agenda
Philipson, Tomas - In: Health Economics 10 (2001) 1, pp. 1-7
No Abstract
Persistent link: https://www.econbiz.de/10005440506
Cover Image
The institute of medicine report on the FDA: where is the science?
Philipson, Tomas; Jena, Anupam B.; Sun, Eric - In: Health Economics 16 (2007) 3, pp. 219-221
No Abstract
Persistent link: https://www.econbiz.de/10005440554
Cover Image
Are drug prices subject to creative destruction? Evidence from the US, 1997–2017
Lichtenberg, Frank R. - In: Health Economics 30 (2021) 8, pp. 1910-1932
Persistent link: https://www.econbiz.de/10012632681
Cover Image
Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003
Lichtenberg, Frank R. - In: Health Economics 18 (2009) 5, pp. 519-534
This study examines the effect of changes in the vintage distribution of cardiovascular system drugs on hospitalization and mortality due to cardiovascular disease using longitudinal country-level data. The vintage of a drug is the first year in which it was marketed anywhere in the world. We...
Persistent link: https://www.econbiz.de/10004992696